Navigation Links
EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
Date:1/30/2009

VIENNA, Austria, January 30 /PRNewswire/ -- EUCODIS Bioscience, a company developing enzymes for the chemical industry, announced today that Thomas Fischer has joined the company as Chief Financial Officer.

"We are excited about the wealth of experience that Thomas brings to EUCODIS Bioscience," said Rudy Pandjaitan, Ph.D., CEO of EUCODIS Bioscience. "His strong background in the life science industry and his close relations with the investment community will be a tremendous asset and help drive the future financial growth of the Company. Thomas joins EUCODIS Bioscience as the Company is launching its first commercial enzyme and is expanding the scope of its industrial collaborations from its current European focus into the US and Asian markets."

Most recently Mr. Fischer served as Chief Financial Officer of Austrianova, a clinical stage biopharmaceutical company that he co-founded in 2001. In this responsibility he successfully raised more than 30 million Euros in two private financing rounds. Prior to that he held senior positions at Aventis CropScience, Germany, and at Nycomed Pharma East Europe/CIS. Before joining the life science industry, Mr. Fischer spent several years in the European consumer goods and construction industries.

Mr. Fischer holds an M.B.A. from Vienna University of Economics and Business Administration, Austria, where he also received his M.Sc.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops enzymes and biocatalytic processes that enable the chemical, pharmaceutical and other industries to establish critical manufacturing processes and to generate superior products.

Based on its proven proprietary technology and led by an experienced management team, EUCODIS Bioscience provides products and services that help its customers to improve efficiencies and to meet growing environmental requirements.

The Company commercializes its enzyme expertise and its versatile and powerful technology in development projects with industrial partners. Current partners include industry leaders such as GlaxoSmithKline, Henkel, and Lohmann Animal Health.

The Company was founded in 2007, as a demerger of the "white biotech" business unit of Eucodis GmbH, a company founded in 2004. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visithttp://www.eucodisbioscience.com

    Company contact:

    Rudy Pandjaitan, PhD
    CEO EUCODIS Bioscience
    Brunner Strasse 59
    A-1230 Vienna
    AUSTRIA
    +43-1-86634-9241
    office@eucodisbioscience.com

    Media Contact:
    Frank Butschbacher
    Investor Relations & Communications
    +43-650-7844940
    office@butschbacher.net
   http://www.butschbacher.net


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
3. BD Biosciences to Distribute FCS Express
4. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
5. Cell Biosciences Introduces Kits for Oncoprotein Analysis
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
8. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
9. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
10. Cell Biosciences Delivers Next Generation System to Stanford University
11. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
Breaking Biology Technology:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):